Trichomonas vaginalis is the most common nonviral etiology of sexually transmitted infection (STI) worldwide. The OSOM Trichomonas rapid test (OSOM; Sekisui Diagnostics, San Diego, CA) is a rapid surrogate to microscopic analysis in symptomatic patients, but its performance in low-prevalence STI populations has been assessed on a limited basis in the literature. OSOM has widespread usage, as accreditation data from the College of American Pathologists report that over 300 participant laboratories utilize this assay on an annual basis. We sought to characterize the analytical and clinical performance of OSOM in a low-prevalence STI population on the basis of a commercial transcription-mediated amplification (TMA) reference
